Loading
Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer.
Martin Reck (LungenClinic Grosshansdorf, Germany) was principal investigator of KEYNOTE-024, which showed pembrolizumab beats platinum chemotherapy in NSCLC with PD-L1 of 50% or more, the first time a checkpoint inhibitor replaced chemotherapy first line. He has led IMpower150 and numerous SCLC immunotherapy trials and has chaired ESMO's lung cancer guideline group.
Useful for a patient offered adagrasib after chemotherapy or immunotherapy who wants the trial explained without jargon. It adds no new data; the primary KRYSTAL-12 publication and the trial page remain the reference for the numbers.
Perioperative immunotherapy is now standard for resectable lung cancer without a targetable driver. The updated overall survival hazard ratio of 0.89, with a confidence interval crossing one, is the honest state of the evidence on whether it cures more people.
The current standard for unresectable stage III lung cancer, and the clearest evidence in the disease that consolidation immunotherapy converts responses into cures for some patients rather than merely delaying relapse.
Read beside the pembrolizumab trial that succeeded at a 50% threshold in the same setting, it is the cleanest demonstration that a PD-L1 threshold is not a property of the protein but of the trial that drew the line.
This trial is why PD-L1 is measured on every new advanced lung cancer and why a patient with a high score can start immunotherapy without chemotherapy. Together with KEYNOTE-189 for the rest of the population, it moved checkpoint inhibitors from second-line rescue to the first treatment most lung cancer patients receive.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer and the tags lung, immunotherapy, trialist.
Shares Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Atezolizumab, PD-1, Pembrolizumab and the tags lung, immunotherapy.
Shares Atezolizumab, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.